Response-Based Dosing for Ponatinib : Model-Based Analyses of the Dose-Ranging OPTIC Study
© 2023 Takeda Pharmaceutical. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
ABL1IS (≥ molecular response with 2-log reduction (MR2)). The exposure-molecular response relationship was described using a four-state, discrete-time Markov model. Time-to-event models were used to characterize the relationship between exposure and arterial occlusive events (AOEs), grade ≥ 3 neutropenia, and thrombocytopenia. Increasing systemic exposures were associated with increasing probability of transitioning from no response to ≥ MR1, and from MR1 to ≥ MR1, with odds ratios of 1.63 (95% confidence interval (CI), 1.06-2.73) and 2.05 (95% CI, 1.53-2.89) for a 15-mg dose increase, respectively. Ponatinib exposure was a significant predictor of AOEs (hazard ratio (HR) 2.05, 95% CI, 1.43-2.93, for a 15-mg dose increase). In the exposure-safety models for neutropenia and thrombocytopenia, exposure was a significant predictor of grade ≥ 3 thrombocytopenia (HR 1.31, 95% CI, 1.05-1.64, for a 15-mg dose increase). Model-based simulations predicted a clinically meaningful higher rate of ≥ MR2 response at 12 months for the 45-mg starting dose (40.4%) vs. 30-mg (34%) and 15-mg (25.2%). The exposure-response analyses supported a ponatinib starting dose of 45 mg with reduction to 15 mg at response for patients with CP-CML.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
---|---|
Enthalten in: |
Clinical pharmacology and therapeutics - 114(2023), 2 vom: 01. Aug., Seite 413-422 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Hanley, Michael J [VerfasserIn] |
---|
Links: |
---|
Themen: |
4340891KFS |
---|
Anmerkungen: |
Date Completed 24.07.2023 Date Revised 25.07.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/cpt.2956 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM357218248 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM357218248 | ||
003 | DE-627 | ||
005 | 20231226072118.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/cpt.2956 |2 doi | |
028 | 5 | 2 | |a pubmed24n1190.xml |
035 | |a (DE-627)NLM357218248 | ||
035 | |a (NLM)37219378 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Hanley, Michael J |e verfasserin |4 aut | |
245 | 1 | 0 | |a Response-Based Dosing for Ponatinib |b Model-Based Analyses of the Dose-Ranging OPTIC Study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.07.2023 | ||
500 | |a Date Revised 25.07.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023 Takeda Pharmaceutical. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
520 | |a Optimizing Ponatinib Treatment in CP-CML (OPTIC) was a randomized, phase II dose-optimization trial of ponatinib in chronic phase-chronic myeloid leukemia (CP-CML) resistant to ≥ 2 tyrosine kinase inhibitors or with T315I mutation. Patients were randomized to starting doses of 45-, 30-, or 15-mg ponatinib once daily. Patients receiving 45- or 30-mg reduced to 15-mg upon achievement of ≤ 1% BCR::ABL1IS (≥ molecular response with 2-log reduction (MR2)). The exposure-molecular response relationship was described using a four-state, discrete-time Markov model. Time-to-event models were used to characterize the relationship between exposure and arterial occlusive events (AOEs), grade ≥ 3 neutropenia, and thrombocytopenia. Increasing systemic exposures were associated with increasing probability of transitioning from no response to ≥ MR1, and from MR1 to ≥ MR1, with odds ratios of 1.63 (95% confidence interval (CI), 1.06-2.73) and 2.05 (95% CI, 1.53-2.89) for a 15-mg dose increase, respectively. Ponatinib exposure was a significant predictor of AOEs (hazard ratio (HR) 2.05, 95% CI, 1.43-2.93, for a 15-mg dose increase). In the exposure-safety models for neutropenia and thrombocytopenia, exposure was a significant predictor of grade ≥ 3 thrombocytopenia (HR 1.31, 95% CI, 1.05-1.64, for a 15-mg dose increase). Model-based simulations predicted a clinically meaningful higher rate of ≥ MR2 response at 12 months for the 45-mg starting dose (40.4%) vs. 30-mg (34%) and 15-mg (25.2%). The exposure-response analyses supported a ponatinib starting dose of 45 mg with reduction to 15 mg at response for patients with CP-CML | ||
650 | 4 | |a Randomized Controlled Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a ponatinib |2 NLM | |
650 | 7 | |a 4340891KFS |2 NLM | |
650 | 7 | |a Imidazoles |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
700 | 1 | |a Diderichsen, Paul |e verfasserin |4 aut | |
700 | 1 | |a Rich, Benjamin |e verfasserin |4 aut | |
700 | 1 | |a Largajolli, Anna |e verfasserin |4 aut | |
700 | 1 | |a Schindler, Emilie |e verfasserin |4 aut | |
700 | 1 | |a Vorog, Alexander |e verfasserin |4 aut | |
700 | 1 | |a Venkatakrishnan, Karthik |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Neeraj |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical pharmacology and therapeutics |d 1960 |g 114(2023), 2 vom: 01. Aug., Seite 413-422 |w (DE-627)NLM000015318 |x 1532-6535 |7 nnns |
773 | 1 | 8 | |g volume:114 |g year:2023 |g number:2 |g day:01 |g month:08 |g pages:413-422 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/cpt.2956 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 114 |j 2023 |e 2 |b 01 |c 08 |h 413-422 |